Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NOTA-RM26
- Development stage
- Phase 1
- Lead developer
- Peking Union Medical College Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
68Ga-NOTA-RM26 is a radiopharmaceutical diagnostic agent composed of RM26, a synthetic bombesin analogue and antagonist of the gastrin-releasing peptide receptor (GRPR), conjugated via the macrocyclic chelator NOTA (1,4,7-triazacyclononane-N,N',N''-triacetic acid) to the positron-emitting radionuclide gallium-68. It is designed for use in positron emission tomography/computed tomography (PET/CT) imaging to non-invasively detect and characterize tumors that overexpress GRPR. The primary mechanism involves selective binding to GRPR on tumor cells, enabling visualization of receptor expression in vivo. This agent has been investigated primarily for imaging high-grade gliomas and prostate cancer, with studies demonstrating its safety and efficacy in distinguishing tumor grades and guiding biopsies[1][3][6][8][9].
- Other names
- gallium Ga 68-NOTA-RM26
02
Targets
GRPR (Gastrin-releasing peptide receptor)
Beyond the preview
Go deeper on 68Ga-NOTA-RM26.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-NOTA-RM26.